S&P 500   4,297.14 (+0.40%)
DOW   33,912.44 (+0.45%)
QQQ   333.06 (+0.81%)
AAPL   173.19 (+0.63%)
MSFT   293.47 (+0.53%)
META   180.89 (+0.22%)
GOOGL   122.08 (+0.33%)
AMZN   143.18 (-0.26%)
TSLA   927.96 (+3.10%)
NVDA   190.32 (+1.73%)
NIO   21.30 (+0.90%)
BABA   94.20 (-0.60%)
AMD   101.01 (+0.18%)
MU   64.70 (-0.52%)
T   18.39 (+0.66%)
CGC   3.82 (+15.76%)
F   16.32 (+0.87%)
GE   79.81 (-0.15%)
DIS   124.26 (+2.21%)
AMC   24.21 (-0.94%)
PYPL   101.51 (+0.41%)
PFE   49.75 (-0.72%)
NFLX   249.11 (-0.08%)
S&P 500   4,297.14 (+0.40%)
DOW   33,912.44 (+0.45%)
QQQ   333.06 (+0.81%)
AAPL   173.19 (+0.63%)
MSFT   293.47 (+0.53%)
META   180.89 (+0.22%)
GOOGL   122.08 (+0.33%)
AMZN   143.18 (-0.26%)
TSLA   927.96 (+3.10%)
NVDA   190.32 (+1.73%)
NIO   21.30 (+0.90%)
BABA   94.20 (-0.60%)
AMD   101.01 (+0.18%)
MU   64.70 (-0.52%)
T   18.39 (+0.66%)
CGC   3.82 (+15.76%)
F   16.32 (+0.87%)
GE   79.81 (-0.15%)
DIS   124.26 (+2.21%)
AMC   24.21 (-0.94%)
PYPL   101.51 (+0.41%)
PFE   49.75 (-0.72%)
NFLX   249.11 (-0.08%)
S&P 500   4,297.14 (+0.40%)
DOW   33,912.44 (+0.45%)
QQQ   333.06 (+0.81%)
AAPL   173.19 (+0.63%)
MSFT   293.47 (+0.53%)
META   180.89 (+0.22%)
GOOGL   122.08 (+0.33%)
AMZN   143.18 (-0.26%)
TSLA   927.96 (+3.10%)
NVDA   190.32 (+1.73%)
NIO   21.30 (+0.90%)
BABA   94.20 (-0.60%)
AMD   101.01 (+0.18%)
MU   64.70 (-0.52%)
T   18.39 (+0.66%)
CGC   3.82 (+15.76%)
F   16.32 (+0.87%)
GE   79.81 (-0.15%)
DIS   124.26 (+2.21%)
AMC   24.21 (-0.94%)
PYPL   101.51 (+0.41%)
PFE   49.75 (-0.72%)
NFLX   249.11 (-0.08%)
S&P 500   4,297.14 (+0.40%)
DOW   33,912.44 (+0.45%)
QQQ   333.06 (+0.81%)
AAPL   173.19 (+0.63%)
MSFT   293.47 (+0.53%)
META   180.89 (+0.22%)
GOOGL   122.08 (+0.33%)
AMZN   143.18 (-0.26%)
TSLA   927.96 (+3.10%)
NVDA   190.32 (+1.73%)
NIO   21.30 (+0.90%)
BABA   94.20 (-0.60%)
AMD   101.01 (+0.18%)
MU   64.70 (-0.52%)
T   18.39 (+0.66%)
CGC   3.82 (+15.76%)
F   16.32 (+0.87%)
GE   79.81 (-0.15%)
DIS   124.26 (+2.21%)
AMC   24.21 (-0.94%)
PYPL   101.51 (+0.41%)
PFE   49.75 (-0.72%)
NFLX   249.11 (-0.08%)
NASDAQ:NXTC

NextCure - NXTC Stock Forecast, Price & News

$5.19
+0.10 (+1.96%)
(As of 08/15/2022 12:00 AM ET)
Add
Compare
Today's Range
$5.01
$5.20
50-Day Range
$4.21
$5.09
52-Week Range
$3.25
$9.18
Volume
103,812 shs
Average Volume
152,868 shs
Market Capitalization
$144.01 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.00

NextCure MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
189.0% Upside
$15.00 Price Target
Short Interest
Healthy
4.40% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.77
Upright™ Environmental Score
News Sentiment
1.50mentions of NextCure in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.55) to ($2.74) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.40 out of 5 stars

Medical Sector

298th out of 1,125 stocks

Pharmaceutical Preparations Industry

145th out of 554 stocks

NXTC stock logo

About NextCure (NASDAQ:NXTC) Stock

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; NC762, an immunomedicine targeting a molecule called human B7 homolog 4 protein, or B7-H4; and NC525, a novel LAIR-1 antibody which is in Preclinical trails that targets acute myeloid leukemia, blast cells, and leukemic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.

NextCure Stock Performance

Shares of NXTC opened at $5.09 on Monday. The firm has a market capitalization of $141.23 million, a price-to-earnings ratio of -1.92 and a beta of -0.10. NextCure has a one year low of $3.25 and a one year high of $9.18. The stock's fifty day moving average is $4.60 and its 200-day moving average is $4.65.

Analyst Upgrades and Downgrades

Separately, Piper Sandler cut their target price on NextCure from $21.00 to $13.00 and set an "overweight" rating on the stock in a research note on Monday, May 23rd. One analyst has rated the stock with a hold rating and four have given a buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $15.00.

Receive NXTC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NextCure and its competitors with MarketBeat's FREE daily newsletter.

NXTC Stock News Headlines

NextCure (NXTC) Investor Presentation - Slideshow
New $2.2 Quadrillion Trend About To Open Up
Massive Opportunities For Investorspixel
The Fed Can't Save Us This Time
The American economy is crumbling, and there's NOTHING Fed Chair Jerome Powell can do to stop it. Today, Dr. Martin Weiss reveals 7 simple steps you can take to protect your wealth from the biggest crisis of our lifetimes. Take action now before it's too late. pixel
See More Headlines
Receive NXTC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NextCure and its competitors with MarketBeat's FREE daily newsletter.

NXTC Company Calendar

Last Earnings
11/04/2021
Today
8/15/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NXTC
Fax
N/A
Employees
87
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$15.00
High Stock Price Forecast
$17.00
Low Stock Price Forecast
$13.00
Forecasted Upside/Downside
+189.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Net Income
$-69,390,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$22.38 million
Book Value
$8.45 per share

Miscellaneous

Free Float
25,305,000
Market Cap
$144.01 million
Optionable
Not Optionable
Beta
-0.10

Key Executives

  • Mr. Michael S. Richman MSBA (Age 61)
    Co-Founder, CEO, Pres & Director
    Comp: $726.42k
  • Dr. Solomon Langermann Ph.D. (Age 62)
    Chief Scientific Officer
    Comp: $527.98k
  • Dr. Han Myint FACP (Age 69)
    M.D., Chief Medical Officer
    Comp: $611.98k
  • Dr. Lieping Chen M.D. (Age 64)
    Ph.D., Co-Founder & Chairman of Scientific Advisory Board
  • Mr. Steven P. Cobourn CPA (Age 59)
    CPA, Chief Financial Officer
  • Dr. Timothy Mayer Ph.D. (Age 57)
    Chief Operating Officer
  • Mr. Sourav Kundu Ph.D. (Age 62)
    Sr. VP of Devel. & Manufacturing













NXTC Stock - Frequently Asked Questions

Should I buy or sell NextCure stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NextCure in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" NXTC shares.
View NXTC analyst ratings
or view top-rated stocks.

What is NextCure's stock price forecast for 2022?

5 brokerages have issued twelve-month target prices for NextCure's shares. Their NXTC share price forecasts range from $13.00 to $17.00. On average, they expect the company's stock price to reach $15.00 in the next year. This suggests a possible upside of 191.8% from the stock's current price.
View analysts price targets for NXTC
or view top-rated stocks among Wall Street analysts.

How have NXTC shares performed in 2022?

NextCure's stock was trading at $6.00 at the start of the year. Since then, NXTC stock has decreased by 14.3% and is now trading at $5.14.
View the best growth stocks for 2022 here
.

When is NextCure's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our NXTC earnings forecast
.

How were NextCure's earnings last quarter?

NextCure, Inc. (NASDAQ:NXTC) issued its earnings results on Thursday, November, 4th. The company reported ($0.65) EPS for the quarter, beating analysts' consensus estimates of ($0.67) by $0.02.

What other stocks do shareholders of NextCure own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NextCure investors own include SCYNEXIS (SCYX), ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Bionano Genomics (BNGO), Novan (NOVN), OrganiGram (OGI), Sorrento Therapeutics (SRNE), Vaxart (VXRT) and DHT (DHT).

When did NextCure IPO?

(NXTC) raised $75 million in an initial public offering on Thursday, May 9th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofAMerrill Lynch, Pierce and Piper Jaffray served as the underwriters for the IPO.

What is NextCure's stock symbol?

NextCure trades on the NASDAQ under the ticker symbol "NXTC."

Who are NextCure's major shareholders?

NextCure's stock is owned by many different retail and institutional investors. Top institutional investors include FMR LLC (1.21%), Renaissance Technologies LLC (1.05%), Assenagon Asset Management S.A. (0.39%), Ikarian Capital LLC (0.26%), Connor Clark & Lunn Investment Management Ltd. (0.24%) and JPMorgan Chase & Co. (0.12%).
View institutional ownership trends
.

How do I buy shares of NextCure?

Shares of NXTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NextCure's stock price today?

One share of NXTC stock can currently be purchased for approximately $5.14.

How much money does NextCure make?

NextCure (NASDAQ:NXTC) has a market capitalization of $142.62 million and generates $22.38 million in revenue each year. The company earns $-69,390,000.00 in net income (profit) each year or ($2.65) on an earnings per share basis.

How can I contact NextCure?

NextCure's mailing address is 9000 VIRGINIA MANOR ROAD SUITE 200, BELTSVILLE MD, 20705. The official website for the company is www.nextcure.com. The company can be reached via phone at (240) 399-4900 or via email at ir@nextcure.com.

This page (NASDAQ:NXTC) was last updated on 8/15/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.